Access the full text.
Sign up today, get DeepDyve free for 14 days.
Lakshminarayana Yerra, Anand Karnad, May Votaw (1997)
Primary breast cancer in aberrant breast tissue in the axilla.Southern medical journal, 90 6
( EguchiY. YoshinakaH. HayashiN. SueyoshiK. UchikuraK. NomotoY. NagataA. SahoH. ShindenY. OhtsukaT. (2021). Accessory breast cancer in the Inframammary Region: A case report and review of the literature. Surgical Case Reports, 7(1), 203.34495428)
EguchiY. YoshinakaH. HayashiN. SueyoshiK. UchikuraK. NomotoY. NagataA. SahoH. ShindenY. OhtsukaT. (2021). Accessory breast cancer in the Inframammary Region: A case report and review of the literature. Surgical Case Reports, 7(1), 203.34495428EguchiY. YoshinakaH. HayashiN. SueyoshiK. UchikuraK. NomotoY. NagataA. SahoH. ShindenY. OhtsukaT. (2021). Accessory breast cancer in the Inframammary Region: A case report and review of the literature. Surgical Case Reports, 7(1), 203.34495428, EguchiY. YoshinakaH. HayashiN. SueyoshiK. UchikuraK. NomotoY. NagataA. SahoH. ShindenY. OhtsukaT. (2021). Accessory breast cancer in the Inframammary Region: A case report and review of the literature. Surgical Case Reports, 7(1), 203.34495428
( Kahraman-CetintasS. Turan-OzdemirS. TopalU. KurtM. GokgozS. SaraydarogluO. OzkanL. (2008). Carcinoma originating from aberrant breast tissue. A case report and review of the literature. Tumori Journal, 94(3), 440–443.18705419)
Kahraman-CetintasS. Turan-OzdemirS. TopalU. KurtM. GokgozS. SaraydarogluO. OzkanL. (2008). Carcinoma originating from aberrant breast tissue. A case report and review of the literature. Tumori Journal, 94(3), 440–443.18705419Kahraman-CetintasS. Turan-OzdemirS. TopalU. KurtM. GokgozS. SaraydarogluO. OzkanL. (2008). Carcinoma originating from aberrant breast tissue. A case report and review of the literature. Tumori Journal, 94(3), 440–443.18705419, Kahraman-CetintasS. Turan-OzdemirS. TopalU. KurtM. GokgozS. SaraydarogluO. OzkanL. (2008). Carcinoma originating from aberrant breast tissue. A case report and review of the literature. Tumori Journal, 94(3), 440–443.18705419
N. Houssami, P. Macaskill, R. Balleine, M. Bilous, M. Pegram (2011)
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysisBreast Cancer Research and Treatment, 129
( YamamuraJ. MasudaN. KodamaY. YasojimaH. MizutaniM. KuriyamaK. ManoM. NakamoriS. SekimotoM. (2012). Male breast cancer originating in an accessory mammary gland in the axilla: A case report. Case Reports in Medicine, 2012, 286210.)
YamamuraJ. MasudaN. KodamaY. YasojimaH. MizutaniM. KuriyamaK. ManoM. NakamoriS. SekimotoM. (2012). Male breast cancer originating in an accessory mammary gland in the axilla: A case report. Case Reports in Medicine, 2012, 286210.YamamuraJ. MasudaN. KodamaY. YasojimaH. MizutaniM. KuriyamaK. ManoM. NakamoriS. SekimotoM. (2012). Male breast cancer originating in an accessory mammary gland in the axilla: A case report. Case Reports in Medicine, 2012, 286210., YamamuraJ. MasudaN. KodamaY. YasojimaH. MizutaniM. KuriyamaK. ManoM. NakamoriS. SekimotoM. (2012). Male breast cancer originating in an accessory mammary gland in the axilla: A case report. Case Reports in Medicine, 2012, 286210.
T. Nguyen, E. El-helou, C. Pop, Ammar Shall, M. Zaiter, Jessica Naccour, X. Ho, Tran Nguyen, Thi Nguyen, Thanh Bui, V. Nguyen, Huu Hoang (2022)
Primary invasive ductal carcinoma of axillary accessory breastInternational Journal of Surgery Case Reports, 98
J. Yamamura, N. Masuda, Y. Kodama, H. Yasojima, M. Mizutani, K. Kuriyama, M. Mano, S. Nakamori, M. Sekimoto (2012)
Male Breast Cancer Originating in an Accessory Mammary Gland in the Axilla: A Case ReportCase Reports in Medicine, 2012
S. Jensen, Peter Thomas, I. Christensen, E. Balslev, Alastair Hansen, E. Høgdall (2020)
Evaluation of analytical accuracy of HER2 status in patients with breast cancerAPMIS, 128
( NguyenT. H. El-HelouE. PopC.-F. ShallA. ZaiterM. NaccourJ. HoX. D. NguyenT. T. NguyenT. M. BuiT. T. NguyenV. C. HoangH. (2022). Primary invasive ductal carcinoma of axillary accessory breast. International Journal of Surgery Case Reports, 98, 107597.36084562)
NguyenT. H. El-HelouE. PopC.-F. ShallA. ZaiterM. NaccourJ. HoX. D. NguyenT. T. NguyenT. M. BuiT. T. NguyenV. C. HoangH. (2022). Primary invasive ductal carcinoma of axillary accessory breast. International Journal of Surgery Case Reports, 98, 107597.36084562NguyenT. H. El-HelouE. PopC.-F. ShallA. ZaiterM. NaccourJ. HoX. D. NguyenT. T. NguyenT. M. BuiT. T. NguyenV. C. HoangH. (2022). Primary invasive ductal carcinoma of axillary accessory breast. International Journal of Surgery Case Reports, 98, 107597.36084562, NguyenT. H. El-HelouE. PopC.-F. ShallA. ZaiterM. NaccourJ. HoX. D. NguyenT. T. NguyenT. M. BuiT. T. NguyenV. C. HoangH. (2022). Primary invasive ductal carcinoma of axillary accessory breast. International Journal of Surgery Case Reports, 98, 107597.36084562
L. Bi, Jun Li, Zhang-zhen Shi, Zhenxing Zhu, Zhenxia Lu (2015)
Male accessory breast cancer successfully treated with endocrine therapy: A case report.Oncology letters, 10 4
( GrosslN. A. (2000). Supernumerary breast tissue. Southern Medical Journal, 93(1), 29–32.10653061)
GrosslN. A. (2000). Supernumerary breast tissue. Southern Medical Journal, 93(1), 29–32.10653061GrosslN. A. (2000). Supernumerary breast tissue. Southern Medical Journal, 93(1), 29–32.10653061, GrosslN. A. (2000). Supernumerary breast tissue. Southern Medical Journal, 93(1), 29–32.10653061
S. G. Jensen, P. E. Thomas, I. J. Christensen, E. Balslev, A. Hansen, E. Høgdall (2020)
Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISHAPMIS, 128
Y. Tsutani, S. Ohsumi, K. Aogi, N. Taira, M. Kataoka, Y. Hamamoto, R. Nishimura, S. Takashima (2006)
A case of metastatic Breast Cancer with HER2 gene amplification that responded completely to single agent trastuzumabBreast Cancer, 13
Yuka Eguchi, H. Yoshinaka, Naoki Hayashi, K. Sueyoshi, K. Uchikura, Yuki Nomoto, Ayako Nagata, Hazuki Saho, Y. Shinden, T. Ohtsuka (2021)
Accessory breast cancer in the inframammary region: a case report and review of the literatureSurgical Case Reports, 7
(2019)
Journal of the European Academy of Dermatology and Venereology welcomes our 10 new Section Editors!Journal of the European Academy of Dermatology and Venereology, 33
(2000)
Supernumerary Breast Tissue
( BiL. LiJ. ShiZ. Z. ZhuZ. X. LuZ. X. (2015). Male accessory breast cancer successfully treated with endocrine therapy: A case report. Oncology Letters, 10(4), 2495–2498.26622878)
BiL. LiJ. ShiZ. Z. ZhuZ. X. LuZ. X. (2015). Male accessory breast cancer successfully treated with endocrine therapy: A case report. Oncology Letters, 10(4), 2495–2498.26622878BiL. LiJ. ShiZ. Z. ZhuZ. X. LuZ. X. (2015). Male accessory breast cancer successfully treated with endocrine therapy: A case report. Oncology Letters, 10(4), 2495–2498.26622878, BiL. LiJ. ShiZ. Z. ZhuZ. X. LuZ. X. (2015). Male accessory breast cancer successfully treated with endocrine therapy: A case report. Oncology Letters, 10(4), 2495–2498.26622878
( GutermuthJ. AudringH. VoitC. HaasN. (2006). Primary carcinoma of ectopic axillary breast tissue. Journal of the European Academy of Dermatology and Venereology, 20(2), 217–221.16441639)
GutermuthJ. AudringH. VoitC. HaasN. (2006). Primary carcinoma of ectopic axillary breast tissue. Journal of the European Academy of Dermatology and Venereology, 20(2), 217–221.16441639GutermuthJ. AudringH. VoitC. HaasN. (2006). Primary carcinoma of ectopic axillary breast tissue. Journal of the European Academy of Dermatology and Venereology, 20(2), 217–221.16441639, GutermuthJ. AudringH. VoitC. HaasN. (2006). Primary carcinoma of ectopic axillary breast tissue. Journal of the European Academy of Dermatology and Venereology, 20(2), 217–221.16441639
( JensenS. G. ThomasP. E. ChristensenI. J. BalslevE. HansenA. HøgdallE. (2020). Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. APMIS, 128(11), 573–582.32860265)
JensenS. G. ThomasP. E. ChristensenI. J. BalslevE. HansenA. HøgdallE. (2020). Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. APMIS, 128(11), 573–582.32860265JensenS. G. ThomasP. E. ChristensenI. J. BalslevE. HansenA. HøgdallE. (2020). Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. APMIS, 128(11), 573–582.32860265, JensenS. G. ThomasP. E. ChristensenI. J. BalslevE. HansenA. HøgdallE. (2020). Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. APMIS, 128(11), 573–582.32860265
Liwei Pang, Meiying Cui, Wanlin Dai, Shuodong Wu, Jing Kong (2021)
Diagnosis and Treatment of Male Accessory Breast Cancer: A Comprehensive Systematic ReviewFrontiers in Oncology, 11
( PangL. CuiM. DaiW. WuS. KongJ. (2021). Diagnosis and treatment of male accessory breast cancer: A comprehensive systematic review. Frontiers in Oncology, 11, Article 640000.)
PangL. CuiM. DaiW. WuS. KongJ. (2021). Diagnosis and treatment of male accessory breast cancer: A comprehensive systematic review. Frontiers in Oncology, 11, Article 640000.PangL. CuiM. DaiW. WuS. KongJ. (2021). Diagnosis and treatment of male accessory breast cancer: A comprehensive systematic review. Frontiers in Oncology, 11, Article 640000., PangL. CuiM. DaiW. WuS. KongJ. (2021). Diagnosis and treatment of male accessory breast cancer: A comprehensive systematic review. Frontiers in Oncology, 11, Article 640000.
Yasuhiro Nihon-yanagi, T. Ueda, N. Kameda, S. Okazumi (2011)
A case of ectopic breast cancer with a literature review.Surgical oncology, 20 1
Jan Gutermuth, Heike Audring, Christiane Voit, Norbert Haas (2006)
Primary carcinoma of ectopic axillary breast tissueJournal of the European Academy of Dermatology and Venereology, 20
( HoussamiN. MacaskillP. BalleineR. L. BilousM. PegramM. D. (2011). HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment, 129(3), 659–674.21698410)
HoussamiN. MacaskillP. BalleineR. L. BilousM. PegramM. D. (2011). HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment, 129(3), 659–674.21698410HoussamiN. MacaskillP. BalleineR. L. BilousM. PegramM. D. (2011). HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment, 129(3), 659–674.21698410, HoussamiN. MacaskillP. BalleineR. L. BilousM. PegramM. D. (2011). HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment, 129(3), 659–674.21698410
( TsutaniY. OhsumiS. AogiK. TairaN. KataokaM. HamamotoY. NishimuraR. TakashimaS. (2006). A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer, 13(4), 374–377.17146166)
TsutaniY. OhsumiS. AogiK. TairaN. KataokaM. HamamotoY. NishimuraR. TakashimaS. (2006). A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer, 13(4), 374–377.17146166TsutaniY. OhsumiS. AogiK. TairaN. KataokaM. HamamotoY. NishimuraR. TakashimaS. (2006). A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer, 13(4), 374–377.17146166, TsutaniY. OhsumiS. AogiK. TairaN. KataokaM. HamamotoY. NishimuraR. TakashimaS. (2006). A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer, 13(4), 374–377.17146166
Sibel Kahraman-Çetintaş, S. Turan-Ozdemir, U. Topal, M. Kurt, S. Gokgoz, O. Saraydaroglu, L. Ozkan (2008)
Carcinoma Originating from Aberrant Breast Tissue. A Case Report and Review of the LiteratureTumori Journal, 94
( Nihon-YanagiY. UedaT. KamedaN. OkazumiS. (2011). A case of ectopic breast cancer with a literature review. Surgical Oncology, 20(1), 35–42.19853438)
Nihon-YanagiY. UedaT. KamedaN. OkazumiS. (2011). A case of ectopic breast cancer with a literature review. Surgical Oncology, 20(1), 35–42.19853438Nihon-YanagiY. UedaT. KamedaN. OkazumiS. (2011). A case of ectopic breast cancer with a literature review. Surgical Oncology, 20(1), 35–42.19853438, Nihon-YanagiY. UedaT. KamedaN. OkazumiS. (2011). A case of ectopic breast cancer with a literature review. Surgical Oncology, 20(1), 35–42.19853438
( YerraL. KarnadA. B. VotawM. L. (1997). Primary breast cancer in aberrant breast tissue in the axilla. Southern Medical Journal, 90(6), 661–662.9191749)
YerraL. KarnadA. B. VotawM. L. (1997). Primary breast cancer in aberrant breast tissue in the axilla. Southern Medical Journal, 90(6), 661–662.9191749YerraL. KarnadA. B. VotawM. L. (1997). Primary breast cancer in aberrant breast tissue in the axilla. Southern Medical Journal, 90(6), 661–662.9191749, YerraL. KarnadA. B. VotawM. L. (1997). Primary breast cancer in aberrant breast tissue in the axilla. Southern Medical Journal, 90(6), 661–662.9191749
Male accessory breast cancer is an extremely rare tumor. There is no report about its monotherapy and subsequent outcome prior to 2022. The current study presents the case of a 76-year-old male patient with a hard mass in the left axilla. Histopathologic examination of an excisional specimen indicated an adenocarcinoma compatible with breast carcinoma. Immunohistochemical analysis demonstrated that the mass was estrogen receptor (ER) (−), progesterone receptor (PR)(−), and human epidermal growth factor receptor type 2 (HER2) (−). A diagnosis of breast cancer originating from the accessory mammary gland in the axilla was made. Two years following surgery, the patient presented with a pulmonary lesion. Core needle biopsy was performed, and the lesion was found to be ER (−), PR(−), and HER2 (3+). The patient was successfully treated with single-agent trastuzumab. Single-agent trastuzumab could be a reasonable regimen for metastatic accessory breast cancer patients with HER2 overexpression for whom chemotherapy and endocrine therapy are not suitable.
American Journal of Men s Health – SAGE
Published: May 1, 2023
Keywords: male accessory breast cancer; HER2; trastuzumab; monotherapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.